SCHEMBL3055962

SCHEMBL3055962

O=C(c1ccccc1)N1CCc2cc(OCc3ccccc3)ccc2C1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 8/20 0.60
ALDH1A1 P00352 1/20 0.55
FFAR1 O14842 1/20 0.55
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
POLB P06746 1/20 0.54
GFER P55789 1/20 0.54
PAX8 Q06710 1/20 0.54
KLF5 Q13887 1/20 0.54
MRGPRX4 Q96LA9 1/20 0.54
CYP2D6 P10635 3/20 0.53
HRH1 P35367 1/20 0.53
KDM4E B2RXH2 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
CARM1 Q86X55 1/20 0.53
ITGB3 P05106 1/20 0.53
ITGA2B P08514 1/20 0.53
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3051707 0.89 HRH3 (0.56) HRH3ALDH1A1FFAR1NPC1RAB9A
SCHEMBL3052486 0.86 MAPK1 (0.64) HRH3FFAR1NPC1RAB9AKDM4E
SCHEMBL27197550 0.84 HRH3 (0.64) HRH3NPC1RAB9AL3MBTL1POLB
SCHEMBL10313047 0.83 PTGS1 (0.51) ALDH1A1FFAR1L3MBTL1CYP2D6
SCHEMBL8239825 0.83 CA1 (0.72) NPC1RAB9ACA1CA2CA7
SCHEMBL23684926 0.82 ESR2 (0.64) HRH3L3MBTL1CYP2D6HRH1CARM1
SCHEMBL24229547 0.81 TMEM97 (0.66) HRH3HRH1
SCHEMBL3056380 0.79 CA1 (0.68) ALDH1A1SMN1; SMN2CA1CA2CA7
SCHEMBL3056740 0.79 KMT2A (0.68) ALDH1A1NPC1KDM4ECA1CA2
SCHEMBL30924689 0.79 HRH3 (0.57) HRH3NPC1RAB9AL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155192-B1 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS STERIX LTD (GB) 2016-09-28 EP disclosed
US-8394825-B2 Compound STERIX LIMITED (GB) 2013-03-12 US disclosed
US-20100222299-A1 COMPOUND STERIX LIMITED (GB) 2010-09-02 US disclosed
CN-101677993-A Compound (I) STERIX LTD 2010-03-24 CN disclosed
EP-2155192-A2 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS Sterix Limited (GB) 2010-02-24 EP disclosed
WO-2008117061-A2 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS STERIX LIMITED (GB) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222299-A1 COMPOUND MKI67, VHL, MYC HRH3 2790/4885ALDH1A1 1517/4885FFAR1 3836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.